Hyo Keun Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyo Keun Lim has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Dongil Choi
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
20 shared publications- Won Jae Lee
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
13 shared publications Hyunchul Rhim
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9 shared publicationsSeong Hyun Kim
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Gangnam-gu, Seoul 135-710, South Korea
6 shared publicationsJae Hoon Lim
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
5 shared publicationsMin Ju Kim
Department of Radiology, Korea University Anam Hospital, Seoul 136-705, Korea
5 shared publications
Latest Publications
- Open Access
- 1 October 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (10) , 1703-1709
Size Discrepancy Between Sonographic and Computed Tomographic/Magnetic Resonance Imaging Measurement of Hepatocellular Carcinoma
Objectives There is no standardized method for size measurement of hepatocellular carcinoma. The purpose of this study was to evaluate whether the size and stage of hepatocellular carcinoma differ according to the imaging modality. Methods This retrospective study was approved by our Institutional Review Board, and written informed consent was waived. Patients with hepatocellular carcinoma who underwent either computed tomography (CT) or magnetic resonance imaging (MRI) along with planning sonography for radiofrequency ablation on the same day were included. A total of 113 patients with 127 hepatocellular carcinomas were included. The sizes of the tumors were measured and the tumor stages were assessed on CT/MRI and sonography. The results were compared by a t test, Bland‐Altman limits of agreement, and a McNemar test. Results There was a significant difference in the hepatocellular carcinoma size between CT/MRI and sonographic measurements (mean difference, 0.26 cm; P < .0001). The sizes of 102 tumors (80.3%) were larger on sonography than on CT/MRI. Twelve tumors (9.5%) were the same size and 13 (10.2%) were smaller on sonography than on CT/MRI. There was also difference in the tumor stage (very early or not) between CT/MRI and sonography (P= .006, McNemar test). The stage was discordant in 16 of 127 tumors (12.6%). Among 69 tumors at the very early stage on CT/MRI, 14 (20.3%) were beyond the very early stage on sonography. Conclusions The size of hepatocellular carcinoma measured on sonography tends to be larger than on CT/MRI; therefore, the tumor stage can differ between sonography and CT/MRI.
- 1 October 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (10) , 1703-1709
Open AccessSize Discrepancy Between Sonographic and Computed Tomographic/Magnetic Resonance Imaging Measurement of Hepatocellular Carcinoma
Objectives There is no standardized method for size measurement of hepatocellular carcinoma. The purpose of this study was to evaluate whether the size and stage of hepatocellular carcinoma differ according to the imaging modality. Methods This retrospective study was approved by our Institutional Review Board, and written informed consent was waived. Patients with hepatocellular carcinoma who underwent either computed tomography (CT) or magnetic resonance imaging (MRI) along with planning sonography for radiofrequency ablation on the same day were included. A total of 113 patients with 127 hepatocellular carcinomas were included. The sizes of the tumors were measured and the tumor stages were assessed on CT/MRI and sonography. The results were compared by a t test, Bland‐Altman limits of agreement, and a McNemar test. Results There was a significant difference in the hepatocellular carcinoma size between CT/MRI and sonographic measurements (mean difference, 0.26 cm; P < .0001). The sizes of 102 tumors (80.3%) were larger on sonography than on CT/MRI. Twelve tumors (9.5%) were the same size and 13 (10.2%) were smaller on sonography than on CT/MRI. There was also difference in the tumor stage (very early or not) between CT/MRI and sonography (P= .006, McNemar test). The stage was discordant in 16 of 127 tumors (12.6%). Among 69 tumors at the very early stage on CT/MRI, 14 (20.3%) were beyond the very early stage on sonography. Conclusions The size of hepatocellular carcinoma measured on sonography tends to be larger than on CT/MRI; therefore, the tumor stage can differ between sonography and CT/MRI.
- 1 May 2011
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 30 (5) , 617-624
Recurrent Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization
- 1 May 2011
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 30 (5) , 617-624
Recurrent Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization
- 1 November 2009
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 193 (5) , W424-W429
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Assessment of Safety in Patients With Ascites
OBJECTIVE. The objective of our study was to assess whether percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a safe procedure in patients with ascites. MATERIALS AND METHODS. From October 2005 to January 2008, 35 patients with one or more HCCs and ascites were referred to our department for planning sonography of RFA. In 15 patients, RFA was determined to be unfeasible. One patient was excluded from the study because of the absence of ascites at the time of RFA. Percutaneous ultrasound-guided RFA was performed in the remaining 19 patients with 24 HCCs. The electrode tract was cauterized at the time of electrode removal. Retrospective assessments of the preprocedural platelet counts and prothrombin times were performed, and patients were evaluated for bleeding complication by checking vital signs, checking serum hemoglobin level, and using CT to determine whether the attenuation value of ascites had increased > 30 HU. RESULTS. There were no cases of mortality or major complications that developed after RFA. No significant difference in the maximum thickness of the perihepatic ascites and in the hemoglobin level between the pre- and postprocedural measurements was detected. Hemoperitoneum as a minor complication was noted in two (10.5%) of 19 patients. However, in those two patients, vital signs were stable, follow-up laboratory data were normal, and hemoperitoneum had been completely absorbed on CT images obtained 1 month after RFA. CONCLUSION. Percutaneous RFA for HCC can be performed safely in patients with ascites.
- 1 November 2009
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 193 (5) , W424-W429
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Assessment of Safety in Patients With Ascites
OBJECTIVE. The objective of our study was to assess whether percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a safe procedure in patients with ascites. MATERIALS AND METHODS. From October 2005 to January 2008, 35 patients with one or more HCCs and ascites were referred to our department for planning sonography of RFA. In 15 patients, RFA was determined to be unfeasible. One patient was excluded from the study because of the absence of ascites at the time of RFA. Percutaneous ultrasound-guided RFA was performed in the remaining 19 patients with 24 HCCs. The electrode tract was cauterized at the time of electrode removal. Retrospective assessments of the preprocedural platelet counts and prothrombin times were performed, and patients were evaluated for bleeding complication by checking vital signs, checking serum hemoglobin level, and using CT to determine whether the attenuation value of ascites had increased > 30 HU. RESULTS. There were no cases of mortality or major complications that developed after RFA. No significant difference in the maximum thickness of the perihepatic ascites and in the hemoglobin level between the pre- and postprocedural measurements was detected. Hemoperitoneum as a minor complication was noted in two (10.5%) of 19 patients. However, in those two patients, vital signs were stable, follow-up laboratory data were normal, and hemoperitoneum had been completely absorbed on CT images obtained 1 month after RFA. CONCLUSION. Percutaneous RFA for HCC can be performed safely in patients with ascites.
- 31 July 2008
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 23 (8pt2) , e422-e427
Percutaneous radiofrequency ablation of hepatocellular adenoma: Initial experience in 10 patients
Background and Aim: The purpose of this study was to assess the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for hepatocellular adenoma.Methods: We performed percutaneous RF ablation in 10 patients with pathologically proven hepatocellular adenomas. Eight patients were asymptomatic and two patients had a recurrent tumor after surgical resection. The size of the tumors was 2.25 ± 0.76 cm (range: 1.5–4.5 cm) in the largest diameter. All ablation procedures were percutaneously performed with an internally cooled RF electrode system under ultrasound (US) guidance. We evaluated the therapeutic efficacy and safety of the procedure by clinical follow‐up data with regular follow‐up computed tomography (CT) for 2–35 months (mean, 17.5 months).Results: All patients well tolerated percutaneous RF ablation procedure without any incident. Contrast‐enhanced CT (n = 7) or contrast‐enhanced US (n = 3) obtained immediately (Conclusion: Percutaneous RF ablation of hepatocellular adenoma without overt complication can be a new potential alternative to close imaging follow‐up or elective surgery.
- 31 July 2008
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 23 (8pt2) , e422-e427
Percutaneous radiofrequency ablation of hepatocellular adenoma: Initial experience in 10 patients
Background and Aim: The purpose of this study was to assess the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for hepatocellular adenoma.Methods: We performed percutaneous RF ablation in 10 patients with pathologically proven hepatocellular adenomas. Eight patients were asymptomatic and two patients had a recurrent tumor after surgical resection. The size of the tumors was 2.25 ± 0.76 cm (range: 1.5–4.5 cm) in the largest diameter. All ablation procedures were percutaneously performed with an internally cooled RF electrode system under ultrasound (US) guidance. We evaluated the therapeutic efficacy and safety of the procedure by clinical follow‐up data with regular follow‐up computed tomography (CT) for 2–35 months (mean, 17.5 months).Results: All patients well tolerated percutaneous RF ablation procedure without any incident. Contrast‐enhanced CT (n = 7) or contrast‐enhanced US (n = 3) obtained immediately (Conclusion: Percutaneous RF ablation of hepatocellular adenoma without overt complication can be a new potential alternative to close imaging follow‐up or elective surgery.
- Open Access
- 1 January 2008
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 9 (1) , 29-37
Sonography Guided Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Effect of Cooperative Training on the Pretreatment Assessment of the Operation's Feasibility
The aim of this study is to investigate the effects of cooperative training on the pretreatment assessment of the feasibility to perform Ultrasonography (US) guided percutaneous radiofrequency ablation for patients afflicted with hepatocellular carcinoma. In our prospective study, 146 patients with 200 hepatocellular carcinomas were referred for radiofrequency ablation after triage by hepatologists. Three radiologists with different levels of experience performed the planning US before (group I) and after (group II) cooperative training, to evaluate whether radiofrequency ablation was feasible. The feasibility rates considered eligible according to our criteria were evaluated. In addition, we analyzed the reasons for the lack of feasibility were analyzed. The interobserver agreement for the assessment of feasibility before and after training was also calculated. The overall feasibility rates for both groups was 73%. No significant difference in the feasibility rates was observed. The feasibility rates of each observer for group I were 71% (observer 1), 77% (observer 2) and 70% (observer 3) and those for group II were 73%, 76% and 69%, respectively. In the tumors (n = 164) considered ineligible, the two most common causes for refraining from performing radiofrequency ablation included non-visualization of the tumor (62%) and the absence of a safe route for the percutaneous approach (38%). We found moderate interobserver agreement for all observers before cooperative training and a good agreement after training. Although the cooperative training did not affect the feasibility rate of each observer, it improved the interobserver agreement for assessing the feasibility of performing US guided radiofrequency ablation, which may reduce unnecessary admission or delayed treatment.
- 1 January 2008
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 9 (1) , 29-37
Open AccessSonography Guided Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Effect of Cooperative Training on the Pretreatment Assessment of the Operation's Feasibility
The aim of this study is to investigate the effects of cooperative training on the pretreatment assessment of the feasibility to perform Ultrasonography (US) guided percutaneous radiofrequency ablation for patients afflicted with hepatocellular carcinoma. In our prospective study, 146 patients with 200 hepatocellular carcinomas were referred for radiofrequency ablation after triage by hepatologists. Three radiologists with different levels of experience performed the planning US before (group I) and after (group II) cooperative training, to evaluate whether radiofrequency ablation was feasible. The feasibility rates considered eligible according to our criteria were evaluated. In addition, we analyzed the reasons for the lack of feasibility were analyzed. The interobserver agreement for the assessment of feasibility before and after training was also calculated. The overall feasibility rates for both groups was 73%. No significant difference in the feasibility rates was observed. The feasibility rates of each observer for group I were 71% (observer 1), 77% (observer 2) and 70% (observer 3) and those for group II were 73%, 76% and 69%, respectively. In the tumors (n = 164) considered ineligible, the two most common causes for refraining from performing radiofrequency ablation included non-visualization of the tumor (62%) and the absence of a safe route for the percutaneous approach (38%). We found moderate interobserver agreement for all observers before cooperative training and a good agreement after training. Although the cooperative training did not affect the feasibility rate of each observer, it improved the interobserver agreement for assessing the feasibility of performing US guided radiofrequency ablation, which may reduce unnecessary admission or delayed treatment.
- 1 August 2007
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 189 (2) , 352-358
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Patterns and Prognostic Factors Based on Clinical and Radiologic Features
OBJECTIVE. The purpose of this study was to elucidate on the basis of clinicoradiologic features the patterns of and prognostic factors for recurrence of hepatocellular carcinoma after liver transplantation.MATERIALS AND METHODS. Institutional review board approval and informed consent were waived for this retrospective study. The subjects were 119 patients (102 men, 17 women; mean age, 49.8 years) with unresectable hepatocellular carcinoma who underwent liver transplantation from September 1996 to May 2005 and survived more than 2 months. We evaluated the incidence, imaging features, cumulative disease-free survival rate, and prognosis for recurrence of hepatocellular carcinoma. We examined clinical, therapeutic, and pretransplantation contrast-enhanced CT findings as prognostic factors and analyzed them with multivariate analysis. The median follow-up period was 17.2 months (range, 2.0-102.4 months).RESULTS. Recurrence was found in 16 (13.4%) of 119 patients and was most frequent in the liver, with no s...
- 1 August 2007
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 189 (2) , 352-358
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Patterns and Prognostic Factors Based on Clinical and Radiologic Features
OBJECTIVE. The purpose of this study was to elucidate on the basis of clinicoradiologic features the patterns of and prognostic factors for recurrence of hepatocellular carcinoma after liver transplantation.MATERIALS AND METHODS. Institutional review board approval and informed consent were waived for this retrospective study. The subjects were 119 patients (102 men, 17 women; mean age, 49.8 years) with unresectable hepatocellular carcinoma who underwent liver transplantation from September 1996 to May 2005 and survived more than 2 months. We evaluated the incidence, imaging features, cumulative disease-free survival rate, and prognosis for recurrence of hepatocellular carcinoma. We examined clinical, therapeutic, and pretransplantation contrast-enhanced CT findings as prognostic factors and analyzed them with multivariate analysis. The median follow-up period was 17.2 months (range, 2.0-102.4 months).RESULTS. Recurrence was found in 16 (13.4%) of 119 patients and was most frequent in the liver, with no s...
- 24 May 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (8) , 2319-2329
Percutaneous Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Hepatectomy: Long-term Results and Prognostic Factors
Background We evaluated the long-term survival results and safety of percutaneous radiofrequency ablation (RFA) for recurrent hepatocellular carcinoma (HCC) after hepatectomy, and assessed the...
- 24 May 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (8) , 2319-2329
Percutaneous Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Hepatectomy: Long-term Results and Prognostic Factors
Background We evaluated the long-term survival results and safety of percutaneous radiofrequency ablation (RFA) for recurrent hepatocellular carcinoma (HCC) after hepatectomy, and assessed the...
- Open Access
- 1 January 2007
- Published by The Korean Society of Radiology in Journal of the Korean Radiological Society
- Vol. 57 (1) , 61-69
Complications Following Radiofrequency Ablation of the Porcine Liver through Portal Vein Penetration: Radiological Findings
Kim SH, et al. J Korean Radiol Soc. 2007 Jul;57(1):61-69. https://doi.org/10.3348/jkrs.2007.57.1.61
- 1 January 2007
- Published by The Korean Society of Radiology in Journal of the Korean Radiological Society
- Vol. 57 (1) , 61-69
Open AccessComplications Following Radiofrequency Ablation of the Porcine Liver through Portal Vein Penetration: Radiological Findings
Kim SH, et al. J Korean Radiol Soc. 2007 Jul;57(1):61-69. https://doi.org/10.3348/jkrs.2007.57.1.61
- 15 December 2006
- Published by Springer Nature in Abdominal Radiology
- Vol. 32 (6) , 719-724
Hemobilia after radiofrequency ablation of hepatocellular carcinoma
- 15 December 2006
- Published by Springer Nature in Abdominal Radiology
- Vol. 32 (6) , 719-724
Hemobilia after radiofrequency ablation of hepatocellular carcinoma